The Limited Times

Now you can see non-English news...

The vaccine from Mexico and Argentina could begin to be produced even before being approved

2020-08-13T05:07:39.952Z


The vaccine, which has not yet been approved and is in phase three of the trials, could be ready in the first half of 2021. Arturo Elías Ayub, spokesperson for the Carlos Slim Foundation, reve ...


Argentina and Mexico will produce the Oxford vaccine 1:07

(CNN Spanish) - The project to produce a possible vaccine against covid-19 to be distributed in Latin America, developed by the AstraZeneca laboratory together with the University of Oxford and funded by the Carlos Slim Foundation, begins this Thursday.

"The process would start tomorrow, that is, the whole process, the transfer of technology, then the manufacturing, the distribution, the whole process, but this agreement was signed last night to start tomorrow, today," said Arturo Elías Ayub, spokesperson for the Carlos Slim Foundation.

The statements of the Carlos Slim Foundation spokesman come hours after the president of Argentina, Alberto Fernández, announced that his country and Mexico will produce this vaccine against covid-19, of which there will be, according to the president, between 150 and 250 million doses for Latin America, with the exception of Brazil.

  • Mexico and Argentina reach an agreement to produce vaccine against covid-19 from AstraZeneca and University of Oxford

"The collaboration between the Foundation and AstraZeneca is a collaboration to be able to start producing a significant amount of inclusive vaccines before it is approved and to take that risk so that in Latin America the vaccine is available as soon as possible and the population can get it" said Arturo Elías Ayub.

The vaccine, which has not yet been approved and is in phase three of the trials, could be ready in the first half of 2021. “If this agreement between AstraZeneca and the Carlos Slim foundation had not been reached, perhaps Latin America would take one more year to receive this vaccine, "said the spokesman.

"What we are doing is getting ahead of ourselves, taking that risk that it seems that everything is on the right track, but there is always a risk that it will not be approved, but by the time it is approved, we are already very advanced in production", he added .

According to Elías Ayub, the pharmaceutical company AstraZeneca looked from the beginning for a single contact for all of Latin America, a single institution that it could trust to ensure this production process.

«There is an alliance with other laboratories in Argentina and Mexico that would be the ones that would provide the equipment to develop the vaccine. The contribution of the foundation is to ensure that all the materials that are needed for the production of the vaccine are purchased, economically ensuring the feasibility that it begins to be produced now, assuming the risk it has, together with the governments of the countries that have this vaccine, if not approved, "said the spokesman for the Slim Foundation.

The Minister of Health of Argentina, Ginés González Garcia, declared this Wednesday the importance of some studies carried out that affirm the extraordinary capacity of this vaccine with a single dose.

"The liquid would come, let's say it like this, from Argentina and it would be packaged in Mexico and from here it is distributed," said the Carlos Slim Foundation spokesman, who added that initially priority will be given to medical personnel, the elderly and other groups risky.

The Secretary of Foreign Affairs of Mexico, Marcelo Ebrard, announced on Twitter that his office and the Ministry of Health will give this Thursday more details of the agreements reached to have the vaccine.

Coronavirus vaccine

Source: cnnespanol

All news articles on 2020-08-13

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.